icad inc. Free Cash Flow Margin

Free Cash Flow Margin of ICAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow Margin growth rates and interactive chart. Free cash flow margin or Free cash flow-to-sales is a performance ratio that measures operating cash flows after deduction of capital expenditures (free cash flow) relative to sales. Free cash flows (FCF) is an important metric in assessing a company's financial condition and determining its intrinsic valuation. FCF/sales is tracked over time and can be compared to a company's historical record or to peers. Free cash flow is useful because it takes out non-cash items out of earnings and only looks at the underlying operating cash coming in and out of a business minus the necessary capital expenditures.


Highlights and Quick Summary

  • Annual Free Cash Flow Margin for 2020 was -25.12% (a 6.22% increase from previous year)
  • Annual Free Cash Flow Margin for 2019 was -23.65% (a 44.83% increase from previous year)
  • Annual Free Cash Flow Margin for 2018 was -16.33% (a -5.99% decrease from previous year)
  • Twelve month Free Cash Flow Margin ending March 30, 2021 was -30.55% (a 21.62% increase compared to previous quarter)
  • Twelve month trailing Free Cash Flow Margin increased by 3.98% year-over-year
Trailing Free Cash Flow Margin for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
-30.55% -25.12% -30.71% -29.38%
Visit stockrow.com/ICAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow Margin of icad inc.

Most recent Free Cash Flow Marginof ICAD including historical data for past 10 years.

Interactive Chart of Free Cash Flow Margin of icad inc.

icad inc. Free Cash Flow Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -25.12%
2019 -23.65%
2018 -16.33%
2017 -17.37%
2016 -22.12%
2015 -6.91%
2014 4.42%
2013 -6.47%
2012 -17.47%
2011 -36.36%
2010 0.54%

Business Profile of icad inc.

Sector: Healthcare
Industry: Health Information Services
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.